Scientists at UC San Francisco are working on a new approach to treating kidney failure that could one day free people from needing dialysis or having to take harsh drugs to suppress their immune system after a transplant.

They have shown for the first time that kidney cells, housed in an implantable device called a bioreactor, can survive inside the body of a pig and mimic several important kidney functions. The device can work quietly in the background, like a pacemaker, and does not trigger the recipient’s immune system to go on the attack.

The findings, published in Nature Communications on August 29, 2023, are an important step forward for The Kidney Project, which is jointly headed by UCSF’s Shuvo Roy, PhD (technical director) and Vanderbilt University Medical Center’s William H. Fissell, MD (medical director).

Eventually, scientists plan to fill the bioreactor with different kidney cells that perform vital functions like balancing the body’s fluids and releasing hormones to regulate blood pressure — then pair it with a device that filters waste from the blood.

The aim is to produce a human-scale device to improve on dialysis, which keeps people alive after their kidneys fail but is a poor substitute for having a real working organ. More than 500,000 people in the U.S. require dialysis several times a week. Many seek kidney transplants, but there are not enough donors, and only about 20,000 people receive them each year. An implantable kidney would be a boon.

“We are focused on safely replicating the key functions of a kidney,” said Roy, a bioengineering professor in the UCSF School of Pharmacy. “The bioartificial kidney will make treatment for kidney disease more effective and also much more tolerable and comfortable.”

Inspired by nature, honed by science

Roy and his colleagues engineered the bioreactor to connect directly to blood vessels and veins, allowing the passage of nutrients and oxygen, much like a transplanted kidney would. Silicon membranes keep the kidney cells inside the bioreactor safe from attack by the recipient’s immune cells.

The team used a type of kidney cell called a proximal tubule cell, which regulates water, as a test case. Co-author H. David Humes, MD, from the University of Michigan, had previously used these cells to help dialysis patients in the intensive care unit with life-saving results.

A green light for The Kidney Project

The team tracked the kidney cells and the recipient animals for seven days after transplantation and both did well. The next step will be month-long trials, as required for by the U.S. Food and Drug Administration (FDA), first in animals and eventually in humans.

“We needed to prove that a functional bioreactor will not require immunosuppressant drugs, and we did,” Roy said. “We had no complications and can now iterate up, reaching for the whole panel of kidney functions at the human scale.”



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Before you post, please prove you are sentient.

What is the outer covering of a tree?

Explore More

AI helps ID cancer risk factors

A novel study from the University of South Australia has identified a range of metabolic biomarkers that could help predict the risk of cancer. Deploying machine learning to examine data

Researchers’ sweeping discovery shows how kidney cells self-renew

University of Texas at Dallas scientists have discovered a previously unknown “housekeeping” process in kidney cells that ejects unwanted content, resulting in cells that rejuvenate themselves and remain functioning and

Kidney models-on-a-chip taking a step toward personalized medicine

Developing advanced drug screening tools is crucial for the advancement of personalized medicine and the creation of more effective treatments. One organ receiving particular attention in this area is the